Ehenbichl, Austria
First Observatory of Precocious Puberty.
Phase
N/ASpan
209 weeksSponsor
Hospices Civils de LyonEcully, Auvergne-Rhône-Alpes
Recruiting
Healthy Volunteers
Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis
This is a multicenter single-arm clinical study including male and female subjects with moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will be enrolled in 10 study sites in France. The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks. The objectives of the study are to assess the efficacy of intravesical instillations of INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is the evaluation of pain using a verbal rating scale one week and four weeks after treatment versus Baseline.
Phase
N/ASpan
63 weeksSponsor
LIDDE TherapeuticsEcully
Recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Phase
N/ASpan
251 weeksSponsor
Hoffmann-La RocheEcully
Recruiting
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Phase
3Span
111 weeksSponsor
Hoffmann-La RocheEcully
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
The Transscleral Photocoagulation sub-study (sub-study 1) will evaluate the effectiveness of using transscleral photocoagulation (TPC) with the Iridex laser system to mitigate vitreous hemorrhages secondary to the Port Delivery System with ranibizumab (PDS) implantation procedure in participants with neovascular age-related macular degeneration (nAMD). The sub-study will enroll about 55 participants. The Re-implantation sub-study (sub-study 2) will evaluate the safety of re-implantation with the updated PDS with ranibizumab . Up to 100 participants who previously participated in the main study in the United States will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
Phase
3Span
576 weeksSponsor
Hoffmann-La RocheEcully
Recruiting
Ecully
Recruiting